SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Background In ambulatory patients with cancer with asymptomatic or pauci-symptomatic SARS-CoV-2 infection, the safety of targeted therapies (TTs), chemotherapy (CT) or immune checkpoint inhibitors (ICIs) therapy is still unknown.Material and methods From the start of the first epidemic wave of SARS-...

Full description

Bibliographic Details
Main Authors: Anna Cecilia Bettini, Maria Grazia Vitale, Matilde De Luca, Barbara Merelli, Sharon Nahm, Paul Lorigan, Andrea Bianchetti, Lucia Bonomi, Andrea Di Croce
Format: Article
Language:English
Published: BMJ Publishing Group 2021-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/2/e001694.full

Internet

https://jitc.bmj.com/content/9/2/e001694.full

Similar Items